Clinical Trial Detail

NCT ID NCT03451331
Title Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Matthew Galsky
Indications

ureter transitional cell carcinoma

transitional cell carcinoma

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Carboplatin + Gemcitabine + Nivolumab

Gemcitabine + Nivolumab + Oxaliplatin

Age Groups: adult senior

No variant requirements are available.